Amb motiu del tancament d'estiu, la validació de documents es reprendrà a partir del 28 d'agost de 2026. Disculpeu les molèsties.
Con motivo del cierre de verano, la validación de documentos se reanudará a partir del 28 de agosto de 2026. Disculpad las molestias
Due to the summer closure, document validation will resume starting August 28, 2026. We apologize for any inconvenience.

Fitxers

914966.pdf (885.21 KB)

Tipus de document

Article

Versió

Versió publicada

Data de publicació

2025-12-01

Llicència de publicació

cc-by-nc-nd (c) Darbà, Josep et al., 2025
Si us plau utilitzeu sempre aquest identificador per citar o enllaçar aquest document: https://hdl.handle.net/2445/230988

Economic burden of heart failure in Europe: A systematic review of costs and cost-effectiveness

Títol de la revista

Autors

Director/Tutor

ISSN de la revista

Títol del volum

Recurs relacionat

https://doi.org/10.1002/ehf2.70017

Resum

Heart failure (HF) affects over 64 million individuals worldwide and is a major cause of hospitalization and mortality, particularly among older adults. In Europe, HF imposes a significant and growing economic burden. This systematic review aimed to evaluate the economic impact of HF diagnosis, treatment and management across European healthcare systems. A systematic literature search was conducted using PubMed, Cochrane Library and Econlit databases including the terms ‘heart failure’ AND ‘costs’ OR ‘cost of illness’ OR ‘cost analysis’ OR ‘economic burden’ OR ‘cost effectiveness’ OR ‘primary care’ OR ‘secondary care’. Studies published between January 2000 and January 2024 were included. A total of 49 studies were included: 17 on resource use, 11 on costs, 15 on resource use and costs, 1 on costs and cost-effectiveness, and 5 on resource use, costs and cost-effectiveness. Hospitalizations and medication use were the most frequently reported resource parameters. Annual HF-related costs varied widely across countries, ranging from €613 to €22,647 per patient. Hospitalizations represented the primary cost driver, accounting for 15% to 92% of total HF costs. Cost-reduction strategies included multidisciplinary care, telemonitoring and pharmacologic interventions. Several disease management programmes reduced hospital admissions and emergency visits. Cost-effectiveness analyses supported the use of certain HF therapies, with incremental cost-effectiveness ratios ranging from €1490 to €9406 per QALY gained. F imposes a substantial economic burden in Europe, largely driven by hospitalizations. Cost-effective interventions such as remote monitoring and integrated care programmes can reduce this burden. Broader adoption of these strategies may improve outcomes and optimize resource allocation across healthcare systems.

Matèries

Insuficiència cardíaca, Política de despesa pública, Salut pública, Anàlisi cost-benefici, Indexació (Documentació)

Matèries (anglès)

Heart failure, Government spending policy, Public health, Cost effectiveness, Indexing

Citació

Col·leccions

Articles publicats en revistes (Economia)

Citació

DARBÀ, Josep, et al. Economic burden of heart failure in Europe: A systematic review of costs and cost-effectiveness. ESC Heart Failure. 2025. Vol. 12, num. 6, pags. 4055-4068. ISSN 2055-5822. [consulted: 28 of August of 2026]. Available at: https://hdl.handle.net/2445/230988

Exportar metadades

JSON - METS

Compartir registre